Kristin Filler1, Debra Lyon2, Nancy McCain3, James Bennett4, Juan Luis Fernández-Martínez5, Enrique Juan deAndrés-Galiana5, R K Elswick3, Nada Lukkahatai6, Leorey Saligan7. 1. National Institute of Nursing Research (NINR), National Institutes of Health (NIH), Bethesda, MD, USA. 2. University of Florida, Gainesville, FL, USA. 3. Virginia Commonwealth University, Richmond, VA, USA. 4. Department of Neurology, Virginia Commonwealth University, Richmond, VA, USA. 5. Department of Mathematics, Universidad de Oviedo, Oviedo, Spain. 6. University of Nevada Las Vegas, Las Vegas, NV, USA. 7. National Institute of Nursing Research (NINR), National Institutes of Health (NIH), Bethesda, MD, USA saliganl@mail.nih.gov.
Abstract
PURPOSE: Mitochondrial dysfunction is a plausible biological mechanism for cancer-related fatigue. Specific aims of this study were to (1) describe the levels of mitochondrial oxidative phosphorylation complex (MOPC) enzymes, fatigue, and health-related quality of life (HRQOL) before and at completion of external beam radiation therapy (EBRT) in men with nonmetastatic prostate cancer (PC); (2) examine relationships over time among levels of MOPC enzymes, fatigue, and HRQOL; and (3) compare levels of MOPC enzymes in men with clinically significant and nonsignificant fatigue intensification during EBRT. METHODS: Fatigue was measured by the revised Piper Fatigue Scale and the Functional Assessment of Cancer Therapy-Fatigue subscale (FACT-F). MOPC enzymes (Complexes I-V) and mitochondrial antioxidant superoxide dismutase 2 were measured in peripheral blood using enzyme-linked immunosorbent assay at baseline and completion of EBRT. Participants were categorized into high or low fatigue (HF vs. LF) intensification groups based on amount of change in FACT-F scores during EBRT. RESULTS: Fatigue reported by the 22 participants with PC significantly worsened and HRQOL significantly declined from baseline to EBRT completion. The HF group comprised 12 men with clinically significant change in fatigue (HF) during EBRT. Although no significant changes were observed in MOPC enzymes from baseline to EBRT completion, there were important differences in the patterns in the levels of MOPC enzymes between HF and LF groups. CONCLUSION: Distinct patterns of changes in the absorbance of MOPC enzymes delineated fatigue intensification among participants. Further investigation using a larger sample is warranted.
PURPOSE:Mitochondrial dysfunction is a plausible biological mechanism for cancer-related fatigue. Specific aims of this study were to (1) describe the levels of mitochondrial oxidative phosphorylation complex (MOPC) enzymes, fatigue, and health-related quality of life (HRQOL) before and at completion of external beam radiation therapy (EBRT) in men with nonmetastatic prostate cancer (PC); (2) examine relationships over time among levels of MOPC enzymes, fatigue, and HRQOL; and (3) compare levels of MOPC enzymes in men with clinically significant and nonsignificant fatigue intensification during EBRT. METHODS:Fatigue was measured by the revised Piper Fatigue Scale and the Functional Assessment of Cancer Therapy-Fatigue subscale (FACT-F). MOPC enzymes (Complexes I-V) and mitochondrial antioxidant superoxide dismutase 2 were measured in peripheral blood using enzyme-linked immunosorbent assay at baseline and completion of EBRT. Participants were categorized into high or low fatigue (HF vs. LF) intensification groups based on amount of change in FACT-F scores during EBRT. RESULTS:Fatigue reported by the 22 participants with PC significantly worsened and HRQOL significantly declined from baseline to EBRT completion. The HF group comprised 12 men with clinically significant change in fatigue (HF) during EBRT. Although no significant changes were observed in MOPC enzymes from baseline to EBRT completion, there were important differences in the patterns in the levels of MOPC enzymes between HF and LF groups. CONCLUSION: Distinct patterns of changes in the absorbance of MOPC enzymes delineated fatigue intensification among participants. Further investigation using a larger sample is warranted.
Authors: Miriam J Johnson; J Martin Bland; Patricia M Davidson; Phillip J Newton; Stephen G Oxberry; Amy P Abernethy; David C Currow Journal: J Pain Symptom Manage Date: 2013-07-30 Impact factor: 3.612
Authors: A P Gimenez-Roqueplo; J Favier; P Rustin; J J Mourad; P F Plouin; P Corvol; A Rötig; X Jeunemaitre Journal: Am J Hum Genet Date: 2001-10-16 Impact factor: 11.025
Authors: Amber S Kleckner; Ian R Kleckner; Eva Culakova; Andrew P Wojtovich; N Jennifer Klinedinst; Sarah L Kerns; Sara J Hardy; Julia E Inglis; Gilbert D A Padula; Karen M Mustian; Michelle C Janelsins; Susan G Dorsey; Leorey N Saligan; Luke J Peppone Journal: Nurs Res Date: 2022-04-13 Impact factor: 2.364
Authors: Amber S Kleckner; Jennifer E Reschke; Ian R Kleckner; Allison Magnuson; Andrea M Amitrano; Eva Culakova; Michelle Shayne; Colleen S Netherby-Winslow; Susan Czap; Michelle C Janelsins; Karen M Mustian; Luke J Peppone Journal: Cancers (Basel) Date: 2022-08-30 Impact factor: 6.575
Authors: Tamara E Lacourt; Elisabeth G Vichaya; Gabriel S Chiu; Robert Dantzer; Cobi J Heijnen Journal: Front Behav Neurosci Date: 2018-04-26 Impact factor: 3.558